<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397198</url>
  </required_header>
  <id_info>
    <org_study_id>CM0120-HYBH</org_study_id>
    <nct_id>NCT04397198</nct_id>
  </id_info>
  <brief_title>The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models</brief_title>
  <acronym>HYBRIDHEART</acronym>
  <official_title>New Imaging-Derived Biomarkers Based On Tridimensional CTA/MRI Hybrid Models For Complex Assessment Of Myocardial Viability After Myocardial Infarction-the HYBRIDHEART Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Med Medical Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Targu Mures, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tîrgu Mureș Emergency Clinical County Hospital, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardio Med Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of HYBRIDHEART study is to develop new imagistic prototype for a complex evaluation&#xD;
      of the myocardial viability by superposing computed tomographic angiographic polar maps of&#xD;
      the myocardium with magnetic resonance imaging contractile maps in subjects who suffered an&#xD;
      acute myocardial infarction. Moreover, the study will evaluate the association of myocardial&#xD;
      viability with the level of inflammatory markers and the percent of myocardial fibrosis, also&#xD;
      will correlate the imaging-derived parameters with the inflammatory status of the patients,&#xD;
      left ventricular function, ischemic time and major adverse cardiovascular events (MACE) rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HYBRIDHEART study is a prospective, observational study that will be conducted in the&#xD;
      Laboratory of Advanced Research in Cardiac Multimodal Imaging of Cardio Med Medical Center&#xD;
      Tîrgu Mureş, Romania.&#xD;
&#xD;
      The project will include 100 subjects with documented ST Segment elevation myocardial&#xD;
      infarction at 30 days prior to study enrollment. The level of inflammatory biomarkers will be&#xD;
      express using hs-CRP levels at day 1 and day 5 post the acute event. All the subjects will&#xD;
      undergo coronary computer tomography angiography (CCTA), magnetic resonance (MRI), 3D&#xD;
      contrast enhancement echocardiography, speckle tracking echocardiography at the moment of the&#xD;
      inclusion. Also, venous blood samples will be collected for the determination of the level of&#xD;
      hs-CRP and myocardial necrosis biomarkers such as I Troponin, myocardial fraction of creatine&#xD;
      kinase (CK-MB).&#xD;
&#xD;
      The imagistic acquisitions obtained from all the techniques used, will be processed using a&#xD;
      supercomputer set up with computational simulations applications for the myocardial kinetics.&#xD;
      All the MRI images will be analyzed using Medis Q-mass software in order to quantify the&#xD;
      myocardial fibrosis, and the CCTA images will be analyzed using SyngoVia. Frontier software,&#xD;
      for the plaques evaluation. The images will be superposed obtaining hybrid CCTA-MRI images&#xD;
      that will be analyzed in order to correlate the degree of plaque vulnerability, the percent&#xD;
      of myocardial scar, the percent of viable myocardial tissue, calculating the total Calcium&#xD;
      Scoring, Syntax score.&#xD;
&#xD;
      The study will be conducted over a period of 2 years, in which the subjects will be examined&#xD;
      at the moment of inclusion and during the follow-up visits. Will be performed the follow up&#xD;
      of the subjects at 1, 3 and 6 months and 1 year after the inclusion period. At 1 month follow&#xD;
      up the subjects will be examined, will be performed echocardiography. Moreover during follow&#xD;
      up will be done telephonic visits with target questions . MACE rate will be assessed at 6&#xD;
      month follow-up and 1 year follow up visits.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
      Primary: to develop new imagistic markers for a complex evaluation of the myocardial&#xD;
      viability, by superposing computed tomographic angiographic polar maps of the myocardium with&#xD;
      MRI contrast enhancement maps in subjects with myocardial infarction.&#xD;
&#xD;
      Secondary: to evaluate the association of the percent of viable myocardium with the level of&#xD;
      inflammatory markers. To correlate the plaque vulnerability markers with the percent of&#xD;
      myocardial fibrosis, the inflammatory status of the subjects, left ventricular function,&#xD;
      ischemic time and the rate of MACE, Calcium Score, Syntax score&#xD;
&#xD;
      Study timeline:&#xD;
&#xD;
      Baseline (day0) Obtain a written consent from the participants on study consent form. Verify&#xD;
      inclusion/exclusion criteria Assess the demographical data of the participants, medical&#xD;
      history, possible known allergies, medication history, alcohol, tobacco use history Physical&#xD;
      examination record Blood pressure record 12-lead ECG Collect venous blood samples Performing&#xD;
      CCTA, MRI, Speckle Tracking Echocardiography using standard protocols&#xD;
&#xD;
      Visit 1 (month 1) Physical examination record 12-lead ECG Blood pressure record Transthoracic&#xD;
      Echocardiography&#xD;
&#xD;
      Visit 2 (month 3) Telephone visit with target questions, all the answers recorded in study&#xD;
      forms.&#xD;
&#xD;
      Visit 3 (month 6) End point evaluation 12-lead ECG Blood pressure record Transthoracic&#xD;
      Echocardiography&#xD;
&#xD;
      Visit 4 (12 months) End point evaluation 12-lead ECG Blood pressure record Transthoracic&#xD;
      Echocardiography Performing CCTA&#xD;
&#xD;
      Study procedures:&#xD;
&#xD;
      Clinical examinations 12 lead ECG Laboratory assessment for the evaluation of the level of&#xD;
      hs-CRP and myocardial necrosis biomarkers (I Troponin, CK-MB) Speckle Tracking&#xD;
      echocardiography with analyzing the myocardial strain, myocardial velocities, left&#xD;
      ventricular function 128-multislice CCTA with the evaluation of the Calcium Scoring (total&#xD;
      and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability&#xD;
      degree, assess polar maps of the myocardium.&#xD;
&#xD;
      MRI for the evaluation of the percentage of myocardial scar, also the percentage of the&#xD;
      viable myocardial tissue using contrast late enhancement sequences, measuring myocardial&#xD;
      fibrosis using Q-mass software.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      A dedicated database will be created, including all the demographical data and data regarding&#xD;
      the acute myocardial infarction, such as: infarct location, time of ischemia, ECG changes,&#xD;
      levels of the necrosis markers, hs-CPR, MRI findings, CCTA findings, speckle tracking&#xD;
      parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hybrid imaging</measure>
    <time_frame>6 months</time_frame>
    <description>the development of the new hybrid imaging features: plaque vulnerability degree, % of myocardial scar, % of viable myocardial tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations</measure>
    <time_frame>12 months</time_frame>
    <description>Association of the level of hs-CRP in relation with MACE rate, time of ischemia, myocardial viability, percent of myocardial fibrotic tissue, plaque vulnerability degree and left ventricular function</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Myocardial Viability</condition>
  <condition>Vulnerable Coronary Plaques</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>HIBRIDH-SG 01</arm_group_label>
    <description>Study subjects with documented ST segment Elevation Myocardial Infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Speckle Tracking echocardiography</intervention_name>
    <description>Diagnostic tests:&#xD;
Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.&#xD;
MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.&#xD;
Diagnostic tests:&#xD;
Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers</description>
    <arm_group_label>HIBRIDH-SG 01</arm_group_label>
    <other_name>128-multislice CCTA</other_name>
    <other_name>MRI</other_name>
    <other_name>Laboratory assessment</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples for evaluation of the level of hs-CRP, myocardial necrosis markers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 subjects with documented ST Segment elevation myocardial infarction at 30 days prior to&#xD;
        study enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged more than 18 years old&#xD;
&#xD;
          -  Patients with documented ST segment Elevation Myocardial Infarction in the last 30&#xD;
             days&#xD;
&#xD;
          -  Patients who signed the written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with renal impairment, or contrast intolerance&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients known with malignancy in the last year&#xD;
&#xD;
          -  Non-compliant patients&#xD;
&#xD;
          -  Patients older than 90 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardio Med</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodora Benedek, Prof</last_name>
      <phone>0722560549</phone>
      <email>theodora.benedek@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Imre Benedek, Prof</last_name>
      <phone>0744626546</phone>
      <email>imrebenedek@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gorea Stanescu Alexandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chitu Monica, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>hybrid images</keyword>
  <keyword>myocardial viability</keyword>
  <keyword>CCTA</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication will be available for interested parties.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The IPD sharing time is starting 6 months after the publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

